Clasp Therapeutics

🗓 Founded 2020👥 32 employees💰 Last funded 2023
Biotechnology Research🌐 clasptx.com
Website LinkedIn
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD. For more information about Clasp, please visit www.clasptx.com
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Clasp Therapeutics?
Clasp Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Clasp Therapeutics last raise funding?
The most recent investment in Clasp Therapeutics recorded on gritt.io was in 2023.
When was Clasp Therapeutics founded?
Clasp Therapeutics was founded in 2020.
What industry is Clasp Therapeutics in?
Clasp Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.